TopFunds

Pfizer Inc.

NYSE: PFE

Stock price

29.58 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1.1
1.2
3.5
1.9
2.9
1.6
3.9
5.5
0.4
1.4
1.4
2%
02Free cash flow per share
2.1
2.3
2.4
2.3
1.8
2.1
5.2
4.5
0.8
1.7
1.6
(2.6)%
03Dividends per share
1.1
1.1
1.3
1.4
1.4
1.5
1.6
1.6
1.6
1.7
1.7
4.4%
04Dividends payout, %
99.6%
1%
36%
71.5%
49.4%
92.2%
39.4%
28.6%
4.3%
1.2%
1.3%
(35.4)%
PROFIT AND LOSS STATEMENT
05Revenue
48,851
52,824
52,546
53,647
41,172
41,651
81,288
100,330
59,553
63,627
62,579
2.5%
06% Change
-
-
-
-
-
-
-
-
-
-
-
2.5%
07Cost of revenue
(13,157)
(15,954)
(15,777)
(16,008)
(12,623)
(11,771)
(34,413)
(38,240)
(29,213)
(21,781)
(18,565)
3.5%
08Gross profit
35,694
36,870
36,769
37,639
28,549
29,880
46,875
62,090
30,340
41,846
44,014
2.1%
09% Margin
73.1%
69.8%
70%
70.2%
69.3%
71.7%
57.7%
61.9%
51%
65.8%
70.3%
66.4% A
10Operating expenses
(22,398)
(22,596)
(22,378)
(22,350)
(21,038)
(20,795)
(26,082)
(24,541)
(25,048)
(25,363)
(28,577)
2.5%
11% of Revenue
(45.9)%
(42.8)%
(42.6)%
(41.7)%
(51.1)%
(49.9)%
(32.1)%
(24.5)%
(42.1)%
(39.9)%
(45.7)%
(41.6)% A
12Operating Income
13,296
14,274
14,391
15,289
7,511
9,085
20,793
37,549
5,292
16,483
15,437
1.5%
13Income tax expense
(1,990)
(1,122)
(9,048)
(706)
(618)
(370)
(1,852)
(3,328)
(1,114)
(28)
(266)
-
14Net Income
6,966
7,215
21,305
11,153
16,273
9,159
22,147
31,365
2,133
8,020
7,770
1.1%
15% Margin
14.3%
13.7%
40.6%
20.8%
39.5%
22%
27.3%
31.3%
3.6%
12.6%
12.4%
21.6% A
16Shares Outstanding
6,257
6,159
6,058
5,977
5,675
5,632
5,708
5,733
5,709
5,700
5,686
(1)%
17EPS Basic
1.1
1.2
3.6
1.9
2.9
1.6
4
5.6
0.4
1.4
1.4
1.9%
18EPS Diluted
1.1
1.2
3.5
1.9
2.9
1.6
3.9
5.5
0.4
1.4
1.4
2%
19EBITDA
15,321
15,294
19,844
19,585
18,813
13,264
30,793
41,031
9,557
18,127
16,783
0.9%
% Margin
31.4%
29%
37.8%
36.5%
45.7%
31.9%
37.9%
40.9%
16.1%
28.5%
26.8%
32.9% A
20Net Interest Income (expense)
(728)
(716)
(879)
(983)
(1,348)
(1,376)
(1,255)
(987)
(585)
(2,546)
(2,068)
11%
21Net Debt / EBITDA
2.3
2.5
2.1
2.1
2.6
2.8
1.1
0.8
7.1
3.6
3.9
2.8 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
3,641
2,595
1,342
1,139
1,121
1,786
1,944
416
2,853
1,043
1,142
(11)%
23Short-term investments
19,649
15,255
18,650
17,694
8,525
10,437
29,125
22,316
9,837
19,434
12,454
(4.5)%
24Accounts receivable
10,838
11,266
11,271
11,399
9,508
11,177
15,745
14,529
15,544
14,777
15,841
3.9%
25Other current assets
2,163
3,050
2,300
12,186
6,581
3,647
3,820
5,017
4,910
4,253
2,807
2.6%
26Inventory
7,513
6,783
7,578
7,508
7,068
8,046
9,059
8,981
10,189
10,851
10,654
3.6%
27Total Current Assets
43,804
38,949
41,141
49,926
32,803
35,067
59,693
51,259
43,333
50,358
42,898
(0.2)%
Non-Current Assets
28Net property, plant & equipment
13,766
13,318
13,865
13,385
12,969
13,745
14,882
16,274
18,940
18,393
21,530
4.6%
29Long-term investments
15,999
7,116
7,015
2,767
20,147
20,262
21,526
15,069
15,368
2,227
1,737
(19.9)%
30Other non-current assets
93,893
112,232
109,774
93,345
101,569
85,156
85,374
114,601
148,860
142,418
141,995
4.2%
31Total Non-Current Assets
123,658
132,666
130,654
109,497
134,685
119,163
121,782
145,944
183,168
163,038
165,262
2.9%
Total Assets
167,460
171,615
171,797
159,422
167,488
154,229
181,477
197,206
226,501
213,396
208,160
2.2%
LIABILITIES
Current Liabilities
32Accounts payable
3,620
4,536
4,656
4,674
3,887
4,283
5,578
6,809
6,710
5,633
5,240
3.8%
33Short-term debt
10,159
10,663
9,940
8,836
16,190
2,703
2,241
2,934
10,346
7,302
3,484
(10.2)%
34Other current liabilities
15,620
15,916
15,831
18,348
17,227
18,934
34,852
32,395
30,738
30,060
28,260
6.1%
35Total Current Liabilities
29,399
31,115
30,427
31,858
37,304
25,920
42,671
42,138
47,794
42,995
36,984
2.3%
Non-Current Liabilities
36Long-term debt
16,629
18,227
5,667
11,563
35,680
35,571
34,757
31,925
60,499
59,691
63,932
14.4%
37Other non-current liabilities
56,355
62,433
64,047
52,243
31,163
29,265
26,586
27,226
28,920
22,213
20,469
(9.6)%
38Total Non-Current Liabilities
72,984
80,660
69,714
63,806
66,843
64,836
61,343
59,151
89,419
81,904
84,401
1.5%
39Total Liabilities
102,383
111,775
100,141
95,664
104,147
90,756
104,014
101,289
137,213
124,899
121,385
1.7%
SHAREHOLDERS` EQUITY
40Common stock
459
461
464
467
468
470
473
476
478
480
481
0.5%
41Retained earnings / (deficit)
71,993
71,774
85,291
89,554
97,670
96,770
103,394
125,656
118,353
116,725
114,610
4.8%
42Accumulated other comprehensive income / (loss)
(9,522)
(11,036)
(9,321)
(11,275)
(11,640)
(11,688)
(5,897)
(8,304)
(7,961)
(7,842)
(8,069)
(1.6)%
43Noncontrolling interests
278
296
348
351
303
235
262
256
274
294
299
0.7%
44Total shareholders' equity
64,998
59,840
71,656
63,758
63,446
63,473
77,463
95,917
89,288
88,497
86,775
2.9%
45Total Liabilities and shareholders' Equity
167,460
171,615
171,797
159,422
167,488
154,229
181,477
197,206
226,501
213,396
208,160
2.2%
46Total Debt
38,899
41,062
42,606
41,745
50,840
38,274
36,998
34,859
70,845
66,993
67,416
5.7%
47Net Debt
35,258
38,467
41,264
40,606
49,719
36,488
35,054
34,443
67,992
65,950
66,274
6.5%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
6,966
7,215
21,305
11,153
16,273
9,159
22,147
31,365
2,133
8,020
7,770
1.1%
49Depreciation & amortization
5,157
5,757
6,269
6,384
5,755
4,777
5,191
5,064
6,290
7,013
6,592
2.5%
50Share-based compensation expense
669
691
840
949
718
756
1,182
872
525
877
799
1.8%
51Changes in working capital and other assets
1,720
2,238
(11,944)
(2,659)
(10,158)
(289)
4,060
(8,034)
(248)
(3,166)
(3,456)
-
52Net cash flows from operating activities
14,512
15,901
16,470
15,827
12,588
14,403
32,580
29,267
8,700
12,744
11,705
(2.1)%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(1,496)
(1,999)
(2,217)
(2,196)
(2,594)
(2,791)
(2,711)
(3,236)
(3,907)
(2,909)
(2,629)
5.8%
54Purchases of investments / marketable securities
(38,123)
(28,186)
(18,133)
(13,474)
(7,036)
(14,402)
(47,613)
(38,780)
(31,178)
(10,313)
(14,650)
(9.1)%
55Proceeds from maturities of marketable securities
52,761
40,690
15,959
19,908
16,340
12,730
28,096
45,462
46,417
8,834
22,690
(8.1)%
56Other investing activities
(16,122)
(18,316)
(350)
287
(10,655)
192
(318)
(19,229)
(43,610)
7,040
(6,762)
(8.3)%
57Net cash flows from investing activities
(2,980)
(7,811)
(4,741)
4,525
(3,945)
(4,271)
(22,546)
(15,783)
(32,278)
2,652
(1,351)
(7.6)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(6,160)
(5,000)
(5,000)
(12,198)
(8,865)
-
-
(2,000)
-
-
-
-
59Dividends paid, net
(6,940)
(7,317)
(7,659)
(7,978)
(8,043)
(8,440)
(8,729)
(8,983)
(9,247)
(9,512)
(9,771)
3.5%
60Debt issuance (repayments), net
1,319
2,606
(941)
(935)
8,764
(12,755)
(1,103)
(3,516)
35,945
(7,159)
(74)
-
61Other financing activities
1,548
790
565
670
(341)
11,546
16
(335)
(632)
(469)
(459)
-
62Net cash flows from financing activities
(10,233)
(8,921)
(13,035)
(20,441)
(8,485)
(9,649)
(9,816)
(14,834)
26,066
(17,140)
(10,304)
0.1%
63Increase (decrease) in cash and cash equivalents
298
(1,046)
(1,253)
(206)
(50)
475
158
(1,515)
2,449
(1,810)
99
(10.4)%
64Cash and equivalents, ending balance
3,641
2,595
1,342
1,225
1,121
1,825
1,983
468
2,917
1,107
1,142
(11)%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
13,016
13,902
14,253
13,631
9,994
11,612
29,869
26,031
4,793
9,835
9,076
(3.5)%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Pfizer Inc. (PFE) financial statements and performance

Explore Pfizer Inc. (PFE) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.